Subclinical Atherosclerosis Noted in Diffuse Scleroderma PDF Print E-mail
Saturday, 15 September 2012 14:29
Patients with diffuse systemic sclerosis (SSc), without any clinical evidence of cardiovascular disease, have indicators of subclinical atherosclerosis, according to a study published online Aug. 16 in Arthritis Care & Research.

To identify signs of early cardiovascular involvement in SSc, Maurizio Turiel, M.D., of the University of Milan, and colleagues conducted a pilot study involving 20 patients with diffuse SSc but no signs of cardiovascular disease, and 20 age- and gender-matched control patients. The researchers found that arterial wall measurements were significantly different in SSc versus control patients.

Compared with controls, in SSc patients, right and left carotid intima-media thickness, pulse wave velocity, and stiffness index β were also significantly elevated. Coronary flow reserve was significantly lower and plasma levels of asymmetric dimethylarginine levels were significantly higher in those with SSc compared with healthy controls. "In conclusion, patients with diffuse SSc seem to have subclinical cardiovascular involvement, as demonstrated by various methods," the authors write. "Further studies are required to define more precise algorithms for assessing and managing cardiovascular disease in SSc patients."

Source: Healthday (2012), "Subclinical Atherosclerosis Noted in Diffuse Scleroderma"; Original article can be viewed here.

 
More articles :

» arGentis Expands Scientific Advisory Board

is a diversified biopharmaceutical development company located in Memphis, Tennessee. The company’s pipeline consists of mid- and late-stage platform technologies in both autoimmunity and ophthalmology. According to , the company announced...

» No Exercise Benefit with Bosentan in Systemic Sclerosis

Treatment with the endothelin receptor antagonist bosentan () failed to improve exercise capacity in patients with systemic sclerosis, a randomized trial found. After one year of treatment, there was a nonsignificant mean change in the six-minute...

» Skin Autofluorescence Is Not Increased in Patients with Systemic Sclerosis

M. E. Hettema, H. Bootsma, R. Graaff, R. de Vries, C. G. M. Kallenberg, and A. J. SmitReceived 24 May 2011; Accepted 8 August 2011Vascular involvement is a key factor in major manifestations of systemic sclerosis (SSc), such as Raynaud’s...

» Interferons As A Potential Treatment For Scleroderma

A variety of new treatments are being currently investigated and developed for the treatment of Systemic in hopes of better controlling symptoms and slowing the progression of the disease. Once such treatment is Interferons, in which recent studies...

» Optical Coherence Tomography: The first Quantitative Imaging Biomarker for Scleroderma

Using the , manufactured in the UK by Michelson Diagnostics Ltd, scientists at the Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds have developed the first quantitative imaging biomarker for skin involvement in . Scleroderma...

» Systemic Sclerosis: An Update

Systemic sclerosis (SSc) is a clinically heterogeneous, systemic disorder affecting connective tissue of skin, internal organs, and walls of blood vessels. It is characterized by alterations of the microvasculature in the form of hypoxia, digital...